Registry-listed formulations

Setipiprant · chembl:CHEMBL2386081

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

3 source entries across 2 studies. This list may not include all unresolved or historical entries.

  • ACT-129968Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Setipiprant 500 mgRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Setipiprant 1000 mgRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)

Phase Distribution

Phase 3
1
25%
Phase 2
2
50%
Phase 1
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

NCT02781311
completedphase_3

Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

NCT01484119
completedphase_1

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

NCT02381496
completedphase_2

Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma

NCT01225315

Clinical Trials (4)

Showing 4 of 4 trials
NCT02781311Phase 2

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

Completed
NCT01484119Phase 3

Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

Completed
NCT02381496Phase 1

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Completed
NCT01225315Phase 2

Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma

Completed

All 4 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
4

External References

ChEMBL
CHEMBL2386081

Names & Codes

Research Codes

ACT-129968KYTH-105